Ignite Creation Date:
2024-05-06 @ 8:59 AM
Last Modification Date:
2024-10-26 @ 12:08 PM
Study NCT ID:
NCT02878642
Status:
UNKNOWN
Last Update Posted:
2017-02-01
First Post:
2016-05-27
Brief Title:
Adherence to Dolutegravir and Outcome
Sponsor:
University Hospital Caen
Organization:
University Hospital Caen
Study Overview
Official Title:
Cohort Study to Assess Electronic-caps Defined Adherence Patterns - Virological Outcome Relationship Amongst HIV-1 Infected Subjects Receiving Dolutegravir-Based Antiretroviral Therapy
Status:
UNKNOWN
Status Verified Date:
2017-01
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DOLUTECAPS
Brief Summary:
The main assumption is that the dolutegravir can get virologic suppression to suboptimal adherence levels between 80 and 95 and after treatment interruptions where other molecules are not capable due to their pharmacokineticpharmacodynamic pardonnance
While the investigators goal is not to compare molecules study with one arm in terms of forgiveness the results of this cohort in terms of forgiveness could be compared to other cohorts available
While the investigators goal is not to compare molecules study with one arm in terms of forgiveness the results of this cohort in terms of forgiveness could be compared to other cohorts available
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None